parasite antigens and do not reflect the entire range of diversity of parasite strains and DTUs infecting humans. While efforts have been made to identify novel parasite antigens for serological diagnostic [8] , an ideal test is still urgently needed [9, 10] . Improved serological tests would allow a better epidemiologic surveillance for the early detection of vectorial, congenital, and oral cases, as well as for the prevention of transfusional cases.
Molecular diagnostic by PCR and quantitative PCR (qPCR) has been refined and standardized, providing key tools for the specific detection, quantification, and genotyping of T. cruzi parasites in a variety of biological and clinical samples [11] [12] [13] . Such methods are proving critical to complement serological diagnostics, patient follow-up after drug treatment, and the unraveling of parasite transmission cycles. However, the use of PCR as a diagnostic tool is still debated, as the extreme sensitivity that has been reached is prone to false positive results and, most importantly, parasite DNA may be present without infection with live parasites, as it has been observed during congenital infection in mouse models [14, 15] . These issues complicate the interpretation of PCR results. On the other hand, molecular genotyping is still insufficiently sensitive, particularly for samples with very low parasite burden [16] . Thus, linking parasite genotypes and DTUs with their biological characteristics, clinical outcomes, and transmission cycles remains elusive [17] , and more sensitive genotyping tests are thus critically needed.
In spite of limited options, drug treatment of infected patients has also progressed over the past ten years. Nifurtimox and benznidazole have a confirmed efficacy in the early stages of infection, particularly in children and young adults. Although more studies are needed, the treatment of women of child-bearing age may also prevent congenital transmission to their newborns [18, 19] . Importantly, a pediatric formulation of benznidazole has been developed under the leadership of Drugs for Neglected Diseases Initiative (DNDi), making drug administration to children easier (Clinicaltrial.gov registration: NCT02625974). However, drug shortage, lack of registration in many countries, poor access to health care, and limited awareness of the disease in both patients and health providers all reduce access to treatment for patients. Current estimates suggest that only 1% have access to these trypanocidal drugs [20, 21] . Eliminating the barriers limiting access to treatment is thus a key priority for the forthcoming years, and this will require strong political commitment. Nonetheless, the results of the long awaited Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial, aimed at evaluating benznidazole treatment in patients with chronic chagasic cardiomyopathy, have stressed the limitations of current treatment [22] . Indeed, while treated patients presented significant decreases in blood parasite levels, they showed no improvement in cardiac clinical outcomes [23] . In addition, the development of new drugs is progressing at a disappointing rate, and there are very few candidates in the development pipeline [21] . Posaconazole, once viewed as a very promising new option, failed to provide sustained reduction in circulating parasites in clinical trials, and other triazoles (i.e., ravuconazole) are not superior to benznidazole [24] . As an alternative, vaccine development against T. cruzi has benefited from a renewed interest [25] due to a better understanding of the delicate host-parasite immune balance, and vaccine development may lead to a valuable additional tool for Chagas disease control.
These recent clinical trials have also pointed out the need for a better understanding of T. cruzi pathogenesis and disease progression. Indeed, the assessment of blood parasite burden by qPCR or the reduction/disappearance of antibodies against the parasite are very imperfect end points to evaluate treatment effectiveness. New biomarkers of disease progression and treatment efficacy are urgently needed for a better follow-up of treated patients. Several candidate molecules have been described [26] but still require extensive clinical validation, which can only be achieved through the development of easy and affordable assays. The dynamics of parasite tissue distribution and the multiclonality of infections are also just beginning to be addressed and may lead to a better understanding of the delicate balance in the host-parasite relationship [27] .
As mentioned above, vector control remains the main preventive intervention against Chagas disease in endemic countries, and it has been very effective at eliminating vectorial transmission by triatomine species that have adapted well to human housing such as Triatoma infestans [28] . Thus, several countries and regions have been declared free of vectorial transmission in the past decade [29] . However, many additional species of triatomines that are more sylvatic but with various degrees of intrusiveness to human habitat are now emerging as important vectors responsible for a significant transmission of T. cruzi to humans [28] . Their control with conventional indoor residual insecticide spraying is poorly effective and thus requires the development of novel integrative interventions based on triatomine ecology. Entomological surveillance and control thus need to be further strengthened and sustained to achieve better vector control.
While we have witnessed striking progress over the past ten years in our understanding and control of Chagas disease, the major challenges highlighted above remain to be addressed to reach the goals of the London declaration on NTD, which aims at eliminating this disease (among others) as a public health concern. There is no doubt that PLOS Neglected Tropical Diseases will continue to support this endeavor by providing a forum for the discussion of these challenges and our progress in addressing them.
